Last updated: February 22, 2026
What is the drug associated with NDC 64980-0690?
The National Drug Code (NDC) 64980-0690 corresponds to Xeris Pharmaceutical's Gvoke (glucagon injection) in single-dose prefilled syringe form. Gvoke is used for the treatment of severe hypoglycemia in type 1 and type 2 diabetes patients.
Market Size and Growth Potential
Current Market Scope
- The global glucagon market was valued at approximately $300 million in 2022.
- It is projected to reach around $590 million by 2027, growing at a compound annual growth rate (CAGR) of nearly 15% (MarketWatch, 2023).
Key Drivers
- Rise in diabetes prevalence: 537 million adults globally have diabetes (International Diabetes Federation, 2021).
- Increased awareness for hypoglycemia management.
- Regulatory approvals for user-friendly formulations; Gvoke's prefilled syringe aligns with this trend.
Major Competitors
| Product |
Formulation |
Price (Approx.) |
Indication |
| Gvoke |
Subcutaneous prefilled syringe |
$150–$175 per unit |
Severe hypoglycemia (vendor focus) |
| Baqsimi (distinct but related) |
Intranasal spray |
$270 per dose |
Emergency hypoglycemia |
| Emergency glucagon kits |
Injectable powder |
$35–$150 per kit |
Severe hypoglycemia |
Market Entry and Adoption
- Gvoke obtained FDA approval in 2019.
- Distribution channels include hospitals, pharmacies, and emergency services.
- Initial market penetration focused on healthcare settings; home use is increasing after adoption by diabetes advocacy groups.
Price Trends and Projections
Historical Pricing Trends
- Initial launch price was approximately $125 per dose.
- Due to manufacturing efficiencies and competition, prices have increased marginally to $150–$175.
Future Price Projections
- Expected to remain stable over the next 2–3 years due to manufacturer competition.
- Price reduction potential exists with increased market penetration and potential biosimilar entries, though biosummies are limited in this segment.
| Year |
Predicted Price Range |
Assumptions |
| 2023 |
$150–$175 |
Stable demand, limited biosimilar entry |
| 2024 |
$145–$170 |
Slight price compression from competing products |
| 2025 |
$140–$165 |
Increased market adoption, price sensitivity, biosimilar risk |
Regulatory and Policy Impact
- Medicare and Medicaid reimbursement policies influence pricing strategies.
- The continued emphasis on emergency medication access incentivizes manufacturers to keep prices moderate.
- No biosimilar entries recognized as of 2023; regulatory pathways for biosimilar glucagon remain under development, which could influence future prices.
Distribution and Reimbursement Considerations
- Reimbursement rates are influenced by CMS policies, insurance coverage, and formulary decisions.
- Patient out-of-pocket costs range from $0 to $50, depending on insurance.
- Access expansion through government and private programs remains critical for market growth.
Key Challenges and Opportunities
- Challenges: Limited biosimilar competition and pricing pressure; high acquisition costs.
- Opportunities: Growing diabetes population; increased awareness; potential for alternative formulations like nasal glucagon.
Summary
NDC 64980-0690 (Gvoke) holds approximately $20–$40 million in annual sales within the U.S., with a strong growth trajectory aligned with diabetes prevalence. Price stability is likely in the short term, with minor decreases possible as competition and biosimilars emerge. Market expansion into home-use segments and broader reimbursement access could further influence pricing.
Key Takeaways
- The drug has a mature but growing market due to increased diabetes prevalence.
- Current prices range from $150–$175 per dose, expected to stay stable or slightly decline.
- Competition, biosimilar development, and policy factors will shape future pricing.
- Distribution relies heavily on healthcare providers and pharmacies, with reimbursement policies impacting access.
- Market growth depends heavily on increased awareness and adoption for emergency hypoglycemia management.
FAQs
1. Will the price of NDC 64980-0690 decrease significantly in the next five years?
It is unlikely unless biosimilars enter the market or manufacturing costs decrease substantially.
2. How does Gvoke compare with intranasal glucagon products?
Gvoke offers a subcutaneous injection, preferred in some clinical settings; intranasal options like Baqsimi provide easier administration but often at a higher per-dose cost.
3. Are biosimilar glucagon products imminent?
As of 2023, biosimilar pathways are under regulatory review but no biosimilar products have received FDA approval yet, limiting near-term price competition.
4. What factors most influence the reimbursement of Gvoke?
Reimbursement depends on insurance coverage, CMS policies, and the drug's inclusion on preferred formularies.
5. Is patient access to Gvoke expected to improve?
Yes, as awareness increases, and distribution channels expand, affordability and access are set to improve, particularly in emergency and home-use settings.
References
- MarketWatch. (2023). Glucagon market forecast. Retrieved from https://www.marketwatch.com
- International Diabetes Federation. (2021). IDF Diabetes Atlas. 9th edition.
- U.S. Food and Drug Administration. (2019). Approval letter for Gvoke.
